Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

News, archive: January 2018

1/31/2018 Pharmaceutical Drug Export from Russia to North Korea (January – November 2017)

Russian export of pharmaceutical drugs is rather unstable, with some unusual destinations. In 2017, North Korea became one of the new export partners for Russia. Between January and November 2017, Russian export of drugs to North Korea increased by 3.7 times in monetary terms (in RUB) and by 5.2 times in physical terms (in units).

1/30/2018 Results of Research Study on Low-Priced VED Import to Russia (January – November 2017)

Between January and November 2017, 86.3% of all imported ready-made pharmaceuticals from the VED list (in monetary terms) had a lower price than recommended by the State Register. In most cases (60.5% of the volume in monetary terms), the difference did not exceed 10 RUB. The difference is most likely due to the peculiarities of the calculation of actual manufacturer prices, as well as the desire of the companies to insure themselves against exports exceeding the register prices.

1/10/2018 Database Update: Pharmaceutical Drug Export from Russia (November 2017)

By the first 11 months of 2017, the exports, excluding exports to EAEU countries, have amounted to 19 bln RUB (including customs duties), which is only 0.4% higher than that of the same period of 2016 (in RUB). However, the positive dynamics alone is somewhat optimistic. The results between January and October 2017 were much more depressing, with the long-term growth rate amounting to -2.2%.